Sutro Biopharma
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
111 Oyster Point Blvd, South San Francis...Phone Number
(650) 881-6500Website
www.sutrobio.comRevenue
$45.7 MillionStock Symbol
STROIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Sutro Biopharma
Sutro Biopharma is a clinical-stage biotechnology company that develops and manufactures engineered cancer therapeutics using its proprietary cell-free protein synthesis platform. The company focuses on antibody-drug conjugates (ADCs) and other precision biologics to advance oncology treatments through research, development, and strategic collaborationsExplore more
Sutro Biopharma Org Chart
AS
Executive Director, Upstream Process Developm...
AH
Strategic Projects Executive Director, Techni...
MF
Senior Director, QC Analytical & Microbiology
BV
Senior Director, Safety Assessment
DE
Director, Purification MSAT
JD
Director, Facilities
AH
Director, Clinical Supply
JA
Director, Vivarium Operations
AR
Associate Director, Supply Chain
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Sutro Biopharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Sutro Biopharma, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Sutro Biopharma launches new products
Check if Sutro Biopharma has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Sutro Biopharma recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Sutro Biopharma
Check out if Sutro Biopharma is spiking on competitors!
Website visits: Recent activity has been detected on your website
Click to see if Sutro Biopharma had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Sutro Biopharma has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Sutro Biopharma
Compare insights from companies similar to Sutro Biopharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$105M
201-500
Public
$237.2M
1997
CE
Celia EckertSenior Vice President, General Counsel & Corporate Secretary
Company Profile Activity
Activity Insights
Sutro Biopharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Sutro Biopharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Sutro Biopharma.
Sutro Biopharma financials insights
Gather financial insights about Sutro Biopharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2007
Series A
$1.5M
2009
Series B
$21.4M
2012
Series C
$36.5M
2013
Series D
$26M
2018
Share Placement
$10M
Stock Offering
$85M
Sutro Biopharma Tech Stack
A closer look at the technologies used by Sutro Biopharma
See more technologies
Most Recent Scoops
Open Position
Open Position
Open Position
Open Position
Project
Clinical Operations
Sutro Biopharma News & Media
Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study
– Encouraging early clinical activity including confirmed and ongoing unconfirmed partial responses with favorable tolerability, and pharmacokinetics (PK) observed in ongoing STRO-004 Phase 1 study –Sutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights
– On track to report initial safety, PK and early activity from Phase 1 dose-escalation trial of STRO-004, potential best-in-class Tissue Factor ADC, in mid-2026 –Here is Why Sutro Biopharma (STRO) is One of the Tiny Stocks That Are On Fire Right Now
Sutro Biopharma Inc. (NASDAQ:STRO) is one of the tiny stocks that are on fire right now. On March 23, Sutro Biopharma reported its full-year 2025 financial results, highlighting a strengthened balance sheet and significant clinical milestones for its antibody-drug conjugate/ADC platform. The company ended 2025 with $141.4 million in cash and marketable securities, which, when […]Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026
STRO-004 demonstrates robust and consistent antitumor activity across multiple TF-expressing solid tumor PDX models, with improved efficacy versus benchmark ADCs
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Sutro Biopharma
Sign Up For FreeTo access detailed company insights
Sutro Biopharma is a clinical-stage biotechnology company that develops and manufactures engineered cancer therapeutics using its proprietary cell-free protein synthesis platform. The company focuses on antibody-drug conjugates (ADCs) and other precision biologics to advance oncology treatments through research, development, and strategic collabora... Read More
